January 2023 in “Journal of The American Academy of Dermatology” This study found that 79% of adolescents with moderate-to-severe alopecia areata treated with baricitinib experienced significant scalp hair regrowth, although further research is needed to confirm these results.
June 2026 in “International Journal of Research in Medical Sciences” This study compared the adverse effects of baricitinib and methotrexate in treating severe alopecia areata and found baricitinib to have a better safety profile, though it was associated with increased cholesterol, triglyceride, and LDL levels.
April 2023 in “Tikrit Journal of Pharmaceutical Sciences” In this study, researchers assessed the effects of deferasirox in 85 children with ß-thalassemia in Kirkuk and reported that while 55.3% experienced a reduction in serum ferritin, 9.4% had adverse effects, indicating that deferasirox is generally well-tolerated as an iron chelator with modifiable side effects.
1 citations
,
December 2016 in “Journal of Evolution of Medical and Dental Sciences” This study found significant associations between pruritus and elevated parathormone levels, and xerosis and elevated serum creatinine levels, in chronic kidney disease patients undergoing haemodialysis.
May 2023 in “Research Square (Research Square)” In this study, researchers observed that treatment with Agaricus subrufescens ethanolic extract improved blood glucose, testosterone levels, and menstrual irregularity in rat models of letrozole-induced Polycystic Ovarian Syndrome, also noting a decrease in elevated liver and ovary weights, suggesting protective effects on renal function.